Alnylam to Webcast Conference Call to Discuss Preliminary Data from Phase II Study of ALN-RSV01

Alnylam to Webcast Conference Call to Discuss Preliminary Data from Phase II Study of ALN-RSV01 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2009-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will host a conference call to discuss the preliminary data from its Phase II study of ALN-RSV01, an RNAi therapeutic in development for the treatment of respiratory syncytial virus (RSV) infection, which is being developed in collaboration with Cubist Pharmaceuticals, Inc. A senior scientific representative from Cubist will also be on the call, which will be held on Monday, June 8, 2009 at 8:30 a.m. ET . To access the call, please dial 866-711-8198 (domestic) or 617-597-5327 (international) five minutes prior to the start time and provide the passcode 62624123. A replay of the call will be available from 11:30 a.m. ET on June 8, 2009 to June 15, 2009 . To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the passcode 24757561. A live audio webcast of the call will also be available on the “Investors” section of the company’s website, www.alnylam.com . An archived webcast will be available on the Alnylam website approximately two hours after the event and will be archived for 14 days. About Alnylam Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world’s top scientific journals including Nature , Nature Medicine , and Cell . The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection and is partnered with Cubist and Kyowa Hakko. In addition, the company is developing RNAi therapeutics for the treatment of a wide range of disease areas, including liver cancers, hypercholesterolemia, Huntington’s disease, and TTR amyloidosis. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic , Novartis , Biogen Idec , Roche , Takeda, Kyowa Hakko, and Cubist. To reflect its outlook for key scientific, clinical, and business initiatives, Alnylam established “ RNAi 2010 ” in January 2008 which includes the company’s plan to significantly expand the scope of delivery solutions for RNAi therapeutics, have four or more programs in clinical development, and to form four or more new major business collaborations, all by the end of 2010. Alnylam and Isis are joint owners of Regulus Therapeutics Inc. , a company focused on the discovery, development, and commercialization of microRNA therapeutics. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts . For more information, please visit www.alnylam.com . Source: Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Investors Cynthia Clayton, 617-551-8207 or Yates Public Relations Media Kathryn Morris, 845-635-9828 For Media Inquiries, please contact: [email protected] For Investor Inquiries, please contact: [email protected] MEDIA KIT Essential assets and documents related to Alnylam VIEW ALL PRESS RELEASES

The release as fetched from its publisher. alnylam.com ↗